Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India
Authors:
Open Access
- 1 June 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 13, 303-313
Abstract
Background: Parenteral iron preparations, like ferric carboxymaltose (FCM), are commonly used to manage moderate-to-severe iron deficiency anemia (IDA). Real-world data on efficacy and safety of FCM is limited in India. Methods: A retrospective, observational and real-world study was conducted to assess the efficacy and safety of FCM in adolescents and adults with IDA across 269 centers in India. Data was retrieved from medical records of patients who received FCM for management of IDA. Physicians’ clinical assessment of efficacy and safety of FCM was also assessed. Data were analyzed for hematological parameters at baseline and at 4 ± 1 week for study population, and for severity of anemia. Results: In 1800 patients with IDA, intravenous FCM resulted in a significant increase in hemoglobin (Hb) of 2.76 g/dL, serum ferritin of 35.85 μg/L, red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) (P < 0.001 for all) at 4 ± 1 week as compared to baseline. In subjects with severe IDA, an increase in Hb was of 3.31 g/dL, serum ferritin increased of 35.84 μg/L, RBC count, hematocrit and MCH improved significantly (P < 0.001 for all). In subjects with moderate IDA, Hb (increase of 2.63 g/dL), serum ferritin (increase of 35.92 μg/L), RBC count, hematocrit, MCV, and MCH improved significantly (P < 0.001 for all). In subjects with mild IDA, only the mean Hb values at 4 weeks were significantly higher (P < 0.001; increased by 1.89 g/dL). Physicians rated efficacy of FCM as very good to good in 97.5% of patients. Similarly, safety of FCM was rated very good to good in 97.2% subjects. Conclusion: FCM efficiently, safely and quickly corrects moderate-to-severe anemia in Indian patients in a short span of 4 weeks. Physicians’ positive clinical impression of efficacy and safety supports clinical usage of FCM in real-world scenario.Keywords
This publication has 36 references indexed in Scilit:
- Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP)Journal of Perinatal Medicine, 2016
- Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled TrialsClinical Drug Investigation, 2015
- Monitoring Recovery from Iron Deficiency Using Total Hemoglobin MassMedicine & Science in Sports & Exercise, 2015
- The retrospective chart review: important methodological considerationsJournal of Educational Evaluation for Health Professions, 2013
- Guideline for the laboratory diagnosis of functional iron deficiencyBritish Journal of Haematology, 2013
- Ferric carboxymaltose for the treatment of iron-deficiency anemiaExpert Opinion on Pharmacotherapy, 2012
- Failure to Follow-Up Test Results for Ambulatory Patients: A Systematic ReviewJournal of General Internal Medicine, 2011
- Ferric CarboxymaltoseDrugs, 2009
- Individualized Treatment for Iron-deficiency Anemia in AdultsThe American Journal of Medicine, 2008
- Laboratory diagnosis of iron-deficiency anemiaJournal of General Internal Medicine, 1992